Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma: China Continuation study

Overview of attention for article published in Journal of Hematology & Oncology, July 2017

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Good Attention Score compared to outputs of the same age (76th percentile)
High Attention Score compared to outputs of the same age and source (83rd percentile)

So far, Altmetric has seen 2 X posts from 2 X users, with an upper bound of 15,340 followers.

RT @Myeloma_Doc: China continuation study of TOURMALINE-MM1 trial shows #Ninlaro/#Revlimid/dex (Rd) -> superior PFS & OS vs. Rd: https://t.…

China continuation study of TOURMALINE-MM1 trial shows #Ninlaro/#Revlimid/dex (Rd) -> superior PFS & OS vs. Rd: https://t.co/UdnqcRjO8u. https://t.co/knr0rT5HyY

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.